(1) Background: Solid dispersion (SD) can help increase the bioavailability of poorly water-soluble drugs. Meanwhile, apixaban (APX)—a new anticoagulation drug—has low water solubility (0.028 mg/mL) and low intestinal permeability (0.9 × 10⁻⁶ cm/s across Caco-2 colonic cells), thus resulting in a low oral bioavailability of <50%; (2) Methods: To solve the drawbacks of conventional APX products, a novel SD of APX in Soluplus^® was prepared, characterized by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and Fourier transform infrared (FTIR) spectroscopy techniques and evaluated for its solubility, intestinal permeability and pharmacokinetic performance. (3) Results: The crystallinity of the prepared APX SD was confirmed. The saturation solubility and apparent permeability coefficient increased 5.9 and 2.54 times compared to that of raw APX, respectively. After oral administration to the rats, the bioavailability of APX SD was improved by 2.31-fold compared to that of APX suspension (4) Conclusions: The present study introduced a new APX SD that potentially exhibits better solubility and permeability, thus increasing APX’s bioavailability.

Background: Postoperative adhesions are a common complication following abdominal surgery, affecting over 90% of patients and leading to significant morbidity. Current anti-adhesion strategies, such as the use of physical and chemical barriers, have limitations such as short retention time, mechanical fragility, and inefficient drug delivery. This study developed a pectin-based emulsion gel loaded with celecoxib to prevent adhesions and provide localized pain relief. Methods: Formulations (F1–F4) with different pectin concentrations were evaluated for rheological properties, mucoadhesion, degradation rate, and celecoxib release. In vivo efficacy was evaluated in Sprague−Dawley rats via a standardized model of peritoneal abrasion, in which the formulations were compared to a commercially available anti-adhesion barrier. Results: The optimized emulsion gel (F4) exhibited improved mucoadhesion (9009 mPa·s), prolonged retention, and controlled celecoxib release over 14 days, reaching 80% release by day 9. In vivo, formulation F4 significantly reduced adhesions compared to a commercially available product. Pharmacokinetic analysis showed rapid absorption (T_max = 2 h) and sustained celecoxib plasma levels, confirming its effectiveness as a localized drug-delivery system. The celecoxib-loaded pectin-based gel successfully prevented postoperative adhesions and provided sustained pain relief. Conclusions: These findings suggest its potential clinical utility, though further preclinical and clinical evaluations are required.